Inmune Bio, Inc. (INMB) - Comprehensive Stock Analysis & Investment Research
Deep dive into Inmune Bio, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.
Inmune Bio, Inc. Investment Summary
When evaluating whether Inmune Bio, Inc. (INMB) represents a compelling investment opportunity, investors must consider multiple factors including the company's financial health, market position, growth prospects, and what our AI-powered predictive models suggest about its near-term price trajectory.
Company Profile
Inmune Bio, Inc. (INMB) operates within the Life Sciences sector, specifically in the Biological Products, (No Diagnostic Substances) industry. The company employs approximately 14 people. With a market capitalization of $35 million, the company is a small-cap stock that may offer higher growth potential but also carries higher volatility.
Financial Performance Analysis
Our comprehensive financial analysis covers Inmune Bio, Inc.'s revenue, profitability metrics, balance sheet strength, and cash flow generation...
AI Price Predictions
Get AI-powered 7-day, 30-day and 90-day price forecasts for Inmune Bio, Inc. along with confidence scores and detailed analysis...
Investment Considerations
Expert analysis of whether Inmune Bio, Inc. is suitable for your investment objectives, risk tolerance, and time horizon...
Corporate Identity
Inmune Bio, Inc. (Stock Symbol: INMB) is a prominent company operating within the Life Sciences sector, with a specific focus on the Biological Products, (No Diagnostic Substances) industry. The company's shares are publicly traded on the Nasdaq exchange.
Leadership & Workforce
Detailed information about Inmune Bio, Inc.'s leadership team, workforce size, and organizational structure...
Market Classification
Market capitalization analysis and stock classification (mega-cap, large-cap, mid-cap, small-cap) for Inmune Bio, Inc....
Sector & Industry Analysis
In-depth sector dynamics and industry context for Inmune Bio, Inc....
Revenue & Growth Analysis
Profitability Metrics
Net profit margin, gross margin, and operating margin analysis for Inmune Bio, Inc....
Market Valuation
P/E ratio, price-to-book, and valuation multiples for Inmune Bio, Inc....
Return Metrics
Return on equity (ROE), return on assets (ROA), and capital efficiency for Inmune Bio, Inc....
Strategic Market Position
Inmune Bio, Inc. strategically competes in the highly dynamic Biological Products, (No Diagnostic Substances) marketplace. As a small-cap company, it represents an emerging market participant with potentially significant growth opportunities. Small-caps often offer greater growth potential as they capture market share and scale their operations, though this comes with higher risk and volatility. Success at this stage can lead to substantial returns for early investors who identify winning business models.
Industry Competitive Landscape
Inmune Bio, Inc. competes within the Life Sciences sector, navigating the competitive dynamics and market forces specific to this industry. The company's competitive position depends on its ability to differentiate through product quality, cost efficiency, customer relationships, or other strategic advantages relevant to its specific market segment.
Operational Efficiency
The company currently shows negative free cash flow of $-47 million . Negative free cash flow may reflect heavy investment in growth, working capital needs, or operational challenges. This is common for high-growth companies investing aggressively but warrants attention for mature businesses.
Margin & Pricing Power Analysis
The company maintains a 64.9% gross margin which reflects exceptional pricing power and/or an asset-light business model. Gross margins at this level are typically seen in software, pharmaceuticals, or luxury goods companies where the cost of incremental production is minimal relative to selling prices. Such margins indicate significant competitive advantages protecting the company from price-based competition.
Operating margin of -31715.3% demonstrates how efficiently the company converts revenues into operating profits after accounting for all operating expenses including research and development, sales and marketing, and general administrative costs. Operating margin compression relative to gross margin suggests high operating expenses that may warrant efficiency improvements or reflect necessary growth investments.
Financial Strength & Leverage
Current ratio of 23.89 demonstrates strong short-term liquidity with current assets significantly exceeding current liabilities. This provides a substantial buffer for meeting near-term obligations and handling unexpected financial needs.